ASCO: Surveillance Viable for Small Renal Masses in Elderly
No adverse effect on kidney cancer-specific survival; lower risk of all-cause death, cardio event
WEDNESDAY, Feb. 13 (HealthDay News) -- For elderly patients with small renal masses, surveillance does not adversely affect kidney cancer-specific survival, and is associated with lower all-cause mortality and risk of cardiovascular events, according to a study presented at the American Society of Clinical Oncology's annual Genitourinary Cancers Symposium, held from Feb. 14 to 16 in Orlando, Fla.
William C. Huang, M.D., from the New York University Medical Center in New York City, and colleagues analyzed data from the surveillance, epidemiology, and end results cancer registry linked with Medicare claims for 8,317 patients aged 66 years and older who were diagnosed with small renal masses (less than 4 cm) between 2000 and 2007.
The researchers found that 70 percent of patients underwent surgery and 31 percent underwent surveillance. From 2000 to 2007 there was a significant increase in the use of surveillance, from 25 to 37 percent. After controlling for patient and disease characteristics, surveillance was associated with a significantly lower risk of death from any cause (hazard ratio, 0.84) and of suffering a cardiovascular event (hazard ratio, 0.79) during a median follow-up of 58 months. There was no significant difference in kidney cancer-specific survival based on treatment approach.
"Our analysis indicates that physicians can comfortably tell an elderly patient, especially a patient that is not healthy enough to tolerate general anesthesia and surgery, that the likelihood of dying of kidney cancer is low and that kidney surgery is unlikely to extend their lives," Huang said in a statement.